A Phase 4 interventional study of Genotropin and Placebo in Brain Injuries and Growth Hormone Deficiency, sponsored by Pfizer. Terminated at 9 sites in 6 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-06-02.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Brain Injuries, Traumatic with a site in France — 24 open to participants now, 26 under way, 2 of them phase 3. Brain Injuries, Traumatic · France.
Among the 98 studies in Brain Injuries, Traumatic with a site in France, this one is the 60th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2008, is one of 5 in phase 4, and was the 5th registered.
1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →24 of the 98 studies in Brain Injuries, Traumatic with a site in France are open now. Recruiting first, the newest first:
Pôle Saint Hélier · Sites in France
Ages 18–55 · Healthy volunteers
Nantes University Hospital · Sites in France
Ages 18–75
Direction Centrale du Service de Santé des Armées · Sites in France
Ages 18–65 · Healthy volunteers
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18–65 · Healthy volunteers
University Hospital Center of Martinique · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 285 Brain Injuries, Traumatic studies recruiting now, 124 (44%) set no upper age limit and 119 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 12 · Phase 4 5
First in 2002; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 52 across 1,090 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 55 across the 66 interventional studies, 172 across the 32 observational. Of the 55 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 98 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
6 of the studies in Brain Injuries, Traumatic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04080440University Hospital, Clermont-FerrandBrain-injured Patients Extubation Readiness Study | 2027-02-13 |
| NCT06830291Direction Centrale du Service de Santé des ArméesValidation and Standardisation of a "Neuralix" Digital Ecological Battery | 2027-03 |
| NCT04534777Assistance Publique - Hôpitaux de ParisMultimodal Neuroprognostication in Disorders of Consciousness | 2027-05 |
| NCT05277519Institut National de la Santé Et de la Recherche Médicale, FranceNeuroplasticity After Proprioceptive Rehabiliation | 2027-06-15 |
| NCT06146062Assistance Publique - Hôpitaux de ParisEffects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury. | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 98 studies in Brain Injuries, Traumatic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.
The study was terminated on 15-Dec-2008 due to an inability to recruit the protocol specified patient population. The study has not been terminated due to any safety concerns.
1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
This study's enrollment of 10 is below the median of 52 across 1,090 interventional studies indexed under Brain Injuries, Traumatic.
Browse Brain Injuries, Traumatic studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Brain Injuries, Traumatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Genotropin
Drug: Placebo
Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
Change From Baseline in the Cognitive Function (CogState™) Composite Score at Week 36
CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.
Time frame: Baseline, Week 36
Change From Baseline in CogState™ at Week 12 and 24.
CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.
Time frame: Baseline, Week 12 and 24
Change From Baseline in Lean Body Mass and Fat Mass at Week 36
The change from Baseline values for lean body mass and fat mass is calculated as the difference between the parameter values at Visit 36, and the parameter values at Baseline.
Time frame: Baseline, Week 36
Change From Baseline in Neurological Outcome as Assessed by Extended Glasgow Outcome Scale (GOS-E) at Week 36
The GOS is widely used for assessing outcome after head injury and non-traumatic acute brain insults and is performed by a physician. The GOS-E uses eight points to assess disability and handicap. The GOS-E focuses on how the injury has affected functioning in major areas of life rather than on the particular deficits and symptoms caused by injury. The overall score ranges from 1-8; 1=Death and 8=Upper Good Recovery
Time frame: Baseline, Week 36
Change From Baseline in Quality of Life Using Short Form (SF)-36 Health Survey at Week 36
A subject administered scale assessing general quality of life. A subject administered score, scale, direction of scale. The SF-36 consists of 36 questions covering the following eight health domains (subscales): Physical Functioning, Bodily Pain, Role Limitations Due to Physical Problems, Role Limitations Due to Emotional Problems, General Health Perceptions, Mental Health, Social Function, Vitality.
Time frame: Baseline, Week 36
Change From Baseline In Assessment of Growth Hormone Deficiency in Adults (AGHDA) Questionnaires at Week 36
The AGHDA is a quality of life subject-administered questionnaire that is condition-specific and comprises of 25 'Yes' or 'No' statements covering 6 dimensions - mobility, pain, energy, sleep, emotional reactions and social isolation. The AGHDA total score change from Baseline values is calculated as the difference between the total score at Visit 6 (Week 36), and the total score at Baseline.
Time frame: Baseline, Week 36
Change From Baseline in Cardiovascular Risk
The cardiovascular risk parameters (low-density lipoprotein-cholesterol, high-density lipoprotein cholesterol, total cholesterol and fasting triglycerides) was measured at all visits (Weeks 2, 4, 12, 24, and 36).
Time frame: Baseline, Weeks 2, 4, 12, 24, and 36
Change From Baseline in Weight
Time frame: Baseline, Weeks 2, 4, 12, 24, and 36
Change From Baseline in Waist Circumference
Time frame: Baseline, Weeks 2, 4, 12, 24, and 36
Due to poor recruitment, the study was terminated early; therefore efficacy analyses were not completed.
| Milestone | Genotropin | Placebo |
|---|---|---|
| Started | 4 | 6 |
| Completed | 2 | 0 |
| Not completed | 2 | 6 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Terminated by sponsor | 2 | 5 |
CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.
No measurements were reported for this outcome.
CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.
No measurements were reported for this outcome.
The change from Baseline values for lean body mass and fat mass is calculated as the difference between the parameter values at Visit 36, and the parameter values at Baseline.
No measurements were reported for this outcome.
The GOS is widely used for assessing outcome after head injury and non-traumatic acute brain insults and is performed by a physician. The GOS-E uses eight points to assess disability and handicap. The GOS-E focuses on how the injury has affected functioning in major areas of life rather than on the particular deficits and symptoms caused by injury. The overall score ranges from 1-8; 1=Death and 8=Upper Good Recovery
No measurements were reported for this outcome.
A subject administered scale assessing general quality of life. A subject administered score, scale, direction of scale. The SF-36 consists of 36 questions covering the following eight health domains (subscales): Physical Functioning, Bodily Pain, Role Limitations Due to Physical Problems, Role Limitations Due to Emotional Problems, General Health Perceptions, Mental Health, Social Function, Vitality.
No measurements were reported for this outcome.
The AGHDA is a quality of life subject-administered questionnaire that is condition-specific and comprises of 25 'Yes' or 'No' statements covering 6 dimensions - mobility, pain, energy, sleep, emotional reactions and social isolation. The AGHDA total score change from Baseline values is calculated as the difference between the total score at Visit 6 (Week 36), and the total score at Baseline.
No measurements were reported for this outcome.
The cardiovascular risk parameters (low-density lipoprotein-cholesterol, high-density lipoprotein cholesterol, total cholesterol and fasting triglycerides) was measured at all visits (Weeks 2, 4, 12, 24, and 36).
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Genotropin | — | 0/4 (0%) | 4/4 (100%) |
| Placebo | — | 0/6 (0%) | 0/6 (0%) |
| Event | Genotropin | Placebo |
|---|---|---|
| PyrexiaGeneral disorders | 1/4 | 0/6 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/4 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/4 | 0/6 |
| SomnolenceNervous system disorders | 1/4 | 0/6 |
| Age, Customized(participants) | Genotropin | Placebo | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| 18 - 44 years | 4 | 4 | 8 |
| 45-64 years | 0 | 2 | 2 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Genotropin | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 4 | 6 | 10 |
The record gives a start of Mar 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone